BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gerding DN, Cornely OA, Grill S, Kracker H, Marrast AC, Nord CE, Talbot GH, Buitrago M, Gheorghe Diaconescu I, Murta de Oliveira C, Preotescu L, Pullman J, Louie TJ, Wilcox MH. Cadazolid for the treatment of Clostridium difficile infection: results of two double-blind, placebo-controlled, non-inferiority, randomised phase 3 trials. Lancet Infect Dis 2019;19:265-74. [PMID: 30709665 DOI: 10.1016/S1473-3099(18)30614-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 6.7] [Reference Citation Analysis]
Number Citing Articles
1 Kullar R, Tran MN, Goldstein EJC. Investigational Treatment Agents for Recurrent Clostridioides difficile Infection (rCDI). J Exp Pharmacol 2020;12:371-84. [PMID: 33116952 DOI: 10.2147/JEP.S242959] [Reference Citation Analysis]
2 Scaiola A, Leibundgut M, Boehringer D, Caspers P, Bur D, Locher HH, Rueedi G, Ritz D. Structural basis of translation inhibition by cadazolid, a novel quinoxolidinone antibiotic. Sci Rep 2019;9:5634. [PMID: 30948752 DOI: 10.1038/s41598-019-42155-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
3 Muhammad A, Simcha W, Rawish F, Sabih R, Albert E, Ali N. Cadazolid vs Vancomycin for the Treatment of Clostridioides difficile Infection: Systematic Review with Meta-analysis. Curr Clin Pharmacol 2020;15:4-10. [PMID: 31376824 DOI: 10.2174/1574884714666190802124301] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
4 Orenstein R, Patron RL. Clostridioides difficile therapeutics: guidelines and beyond. Ther Adv Infect Dis 2019;6:2049936119868548. [PMID: 31448117 DOI: 10.1177/2049936119868548] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
5 Czepiel J, Krutova M, Mizrahi A, Khanafer N, Enoch DA, Patyi M, Deptuła A, Agodi A, Nuvials X, Pituch H, Wójcik-Bugajska M, Filipczak-Bryniarska I, Brzozowski B, Krzanowski M, Konturek K, Fedewicz M, Michalak M, Monpierre L, Vanhems P, Gouliouris T, Jurczyszyn A, Goldman-Mazur S, Wultańska D, Kuijper EJ, Skupień J, Biesiada G, Garlicki A. Mortality Following Clostridioides difficile Infection in Europe: A Retrospective Multicenter Case-Control Study. Antibiotics (Basel) 2021;10:299. [PMID: 33805755 DOI: 10.3390/antibiotics10030299] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Selle K, Fletcher JR, Tuson H, Schmitt DS, McMillan L, Vridhambal GS, Rivera AJ, Montgomery SA, Fortier LC, Barrangou R, Theriot CM, Ousterout DG. In Vivo Targeting of Clostridioides difficile Using Phage-Delivered CRISPR-Cas3 Antimicrobials. mBio 2020;11:e00019-20. [PMID: 32156803 DOI: 10.1128/mBio.00019-20] [Cited by in Crossref: 24] [Cited by in F6Publishing: 11] [Article Influence: 12.0] [Reference Citation Analysis]
7 Bouza E, Aguado JM, Alcalá L, Almirante B, Alonso-Fernández P, Borges M, Cobo J, Guardiola J, Horcajada JP, Maseda E, Mensa J, Merchante N, Muñoz P, Pérez Sáenz JL, Pujol M, Reigadas E, Salavert M, Barberán J. Recommendations for the diagnosis and treatment of Clostridioides difficile infection: An official clinical practice guideline of the Spanish Society of Chemotherapy (SEQ), Spanish Society of Internal Medicine (SEMI) and the working group of Postoperative Infection of the Spanish Society of Anesthesia and Reanimation (SEDAR). Rev Esp Quimioter 2020;33:151-75. [PMID: 32080996 DOI: 10.37201/req/2065.2020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
8 Chiu CW, Tsai PJ, Lee CC, Ko WC, Hung YP. Application of Microbiome Management in Therapy for Clostridioides difficile Infections: From Fecal Microbiota Transplantation to Probiotics to Microbiota-Preserving Antimicrobial Agents. Pathogens 2021;10:649. [PMID: 34073695 DOI: 10.3390/pathogens10060649] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Speri E, Janardhanan J, Masitas C, Schroeder VA, Lastochkin E, Wolter WR, Fisher JF, Mobashery S, Chang M. Discovery of a Potent Picolinamide Antibacterial Active against Clostridioides difficile. ACS Infect Dis 2020;6:2362-8. [PMID: 32786277 DOI: 10.1021/acsinfecdis.0c00479] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
10 Carlson TJ, Gonzales-luna AJ. Antibiotic Treatment Pipeline for Clostridioides difficile Infection (CDI): A Wide Array of Narrow-Spectrum Agents. Curr Infect Dis Rep 2020;22. [DOI: 10.1007/s11908-020-00730-1] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]